Investor Presentaiton

ENHERTU FY2022 approval status Daiichi-Sankyo HER2+ BC 2L ■May 2022: FDA approval based on Priority Review, Breakthrough Therapy Designation and Real Time Oncology Review program ■■■Jul 2022: EMA approval * Approval also obtained in the countries joining Project Orbis (Brazil, Australia, Israel, Canada, Switzerland) in FY2022 H1 BC: breast cancer 23

View entire presentation